On February 25, 2009, the Company was granted
an exclusive, worldwide, transferable, perpetual license (License)
to use certain proprietary technology for the processing of lithium
for use in batteries and other fields. A patent application
relating to the licensed technology is pending.
In exchange for the License, the
Company:
(1) issued 1,000,000 shares of
common stock of the Company;
(2) issued an additional
2,000,000 shares of common stock of the Company which are
restricted and subject to forfeiture if there has not been at least
$1,000,000 in total commercial sales of licenses products within
three years (Threshold);
(3) will pay royalties of $1.00
per kilogram, of lithium products manufactured and sold, payable
quarterly;
(4) will pay a royalty of $.01
per kilogram, of excess products manufactured and sold, payable
quarterly;
(5) will grant options to
purchase up to a total of 19% (inclusive of previously issued
shares) of the issued and outstanding shares of the Company upon
the issuance of any additional shares after the date of the
License. These options are exercisable at the same prices as the
shares sold or values received for five years from each grant date.
These grants are only issuable if the Threshold is met.
Upon a transfer of the entire
License, the Company shall pay the licensor a fee equal to 19% of
all compensation received on the transfer.
The License has been recorded at
its fair value of $250,000 based on management’s projected
net cash flows to be realized from sales of products under the
License.
Pursuant to the terms of the
License Agreement, the additional 2,000,000 shares of the
Company’s common stock, which were issued, are subject to
forfeiture if there has not been at least $1,000,000 in total
commercial sales of licenses products by February 25,
2012.
As of February 25, 2012,
commercial sales of the licensed products have not
commenced.
As of December 31, 2011, the
Company has evaluated the fair value of the Technology License
intangible asset and has determined that it is in excess of the
carrying value based on our estimated net discounted cash flows
anticipated from the sale of the process under the licensing
agreement. The Company has also continued to test the process and
believes that it is workable and commercially feasible.